All In Biotech

Drug Trial Radar · NCT05507580

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 461 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

461

Actual

Start

May 29, 2023

Primary completion

Jul 11, 2024

Study completion Aug 15, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study evaluates the dosing flexibility of upadacitinib in adult participants with moderate to severe AD. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for the treatment of moderate to severe/active immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's Disease (CD), and AD. The study is comprised of a 35-day Screening Period, a 12-week double-blind period and a 12-week single-blind period. During the double-blind period, participants are placed in 1 of 2 groups, called treatment arms and will be randomized in a 1:1 ratio to receive upadacitinib. At 12 weeks during the single blind period, participants will be blinded to the upadacitinib dose based on their EASI response and reassigned to in 1 of 4 arms. After the last study visit, there is a 30-day follow-up visit. Approximately 454 adult participants ages 18 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 160 sites worldwide. The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Atopic Dermatitis

Interventions

  • UpadacitinibDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24Time frame: Baseline and Week 24

Locations

106 sites in 18 countries. Site status is shown where the registry gives one.

  • Momentum Clinical Research /ID# 254028

    Darlinghurst, New South Wales, Australia

  • Premier Specialist /ID# 246150

    Kogarah, New South Wales, Australia

  • Veracity Clinical Research /ID# 246154

    Woolloongabba, Queensland, Australia

  • North Eastern Health Specialists /ID# 246153

    Campbelltown, South Australia, Australia

  • Skin Health Institute Inc /ID# 246146

    Carlton, Victoria, Australia

  • CHU de Liege /ID# 245839

    Liège, Belgium

  • Cliniques Universitaires UCL Saint-Luc /ID# 245842

    Woluwe-Saint-Lambert, Brussels Capital, Belgium

  • Grand Hôpital De Charleroi - Notre Dame /ID# 245837

    Charleroi, Hainaut, Belgium

  • AZ Sint-Lucas /ID# 253708

    Ghent, Oost-Vlaanderen, Belgium

  • Dermatologie Maldegem /ID# 245840

    Maldegem, Oost-Vlaanderen, Belgium

  • Medical center Cordis /ID# 253310

    Pleven, Bulgaria

  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 246395

    Sofia, Bulgaria

  • Ambulatory for Specialized Medical Care for skin and venereal diseases /ID# 247027

    Sofia, Bulgaria

  • Medical Center Euroderma /ID# 246736

    Sofia, Bulgaria

  • Medical center EuroHealth /ID# 246305

    Sofia, Bulgaria

  • UMHAT Alexandrovska EAD /ID# 246594

    Sofiya, Sofia, Bulgaria

  • Dermatology Research Institute - Blackfoot Trail /ID# 246703

    Calgary, Alberta, Canada

  • Beacon Dermatology Inc /ID# 246705

    Calgary, Alberta, Canada

  • Rejuvenation Dermatology - Edmonton Downtown /ID# 256790

    Edmonton, Alberta, Canada

  • Alberta DermaSurgery Centre /ID# 247286

    Edmonton, Alberta, Canada

  • Dr. Chih-ho Hong Medical Inc. /ID# 246700

    Surrey, British Columbia, Canada

  • Lynde Institute for Dermatology /ID# 246699

    Markham, Ontario, Canada

  • SKiN Centre for Dermatology /ID# 246702

    Peterborough, Ontario, Canada

  • Private Practice - Dr. Kim Papp Clinical Research /ID# 246698

    Waterloo, Ontario, Canada

  • Beijing Friendship Hospital /ID# 247719

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital /ID# 247842

    Beijing, Beijing Municipality, China

  • Dermatology Hospital of Southern Medical University /ID# 247951

    Guangzhou, Guangdong, China

  • The First Hospital of China Medical University /ID# 247686

    Shenyang, Liaoning, China

  • Huashan Hospital, Fudan University /ID# 247680

    Shanghai, Shanghai Municipality, China

  • Elbe Klinikum Buxtehude /ID# 245626

    Buxtehude, Germany

  • Derma Study Center Friedrichshafen GmbH /ID# 245640

    Friedrichshafen, Germany

  • Universitaetsklinikum Halle (Saale) /ID# 245637

    Halle, Germany

  • Dermatologikum Hamburg /ID# 245635

    Hamburg, Germany

  • Dermatologie Quist-BAG Dres. med. Quist PartG /ID# 245628

    Mainz, Germany

  • Dermatologische Gemeinschaftspraxis Mahlow /ID# 245629

    Blankenfelde-Mahlow, Brandenburg, Germany

  • Klinikum Darmstadt /ID# 247028

    Darmstadt, Hesse, Germany

  • Universitaetsklinikum Frankfurt /ID# 245627

    Frankfurt am Main, Hesse, Germany

  • Fachklinik Bad Bentheim /ID# 245634

    Bad Bentheim, Lower Saxony, Germany

  • Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 245636

    Bramsche, Lower Saxony, Germany

  • Universitaetsklinikum Muenster /ID# 245623

    Münster, North Rhine-Westphalia, Germany

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.